Literature DB >> 23419136

Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw.

M S Najm1, D H Solomon, S-B Woo, N S Treister.   

Abstract

BACKGROUND AND
OBJECTIVE: Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is an emerging oral complication that occurs most commonly in the setting of high-dose bisphosphonate therapy for cancer. The purpose of this study was to estimate the health care-related costs associated with a diagnosis of BONJ in patients with cancer evaluated and managed at one tertiary oral medicine practice.
METHODS: This was a retrospective electronic medical record review of cancer patients with BONJ. All health care-related resources were abstracted using a structured chart abstraction tool; data captured included medications, imaging studies, laboratory investigations, procedures, and visits. Standardized references were used to assign costs in 2010 US dollars.
RESULTS: Ninety-two cancer patients with BONJ were identified who were followed for a median of 12 months. The median cost of a case of BONJ was $1667 (interquartile range from $976 to $3350). Medication costs comprised the majority (42%) of the total costs, followed by procedural interventions (22%), clinic visits (19.5%), and imaging studies (13.8%). Patient factors associated with higher median costs included a greater number of involved oral quadrants and more advanced BONJ stage.
CONCLUSION: There are considerable costs associated with the diagnosis and management of BONJ in patients with cancer, with medications accounting for nearly half of resource expenditures.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BONJ; Osteonecrosis; bisphosphonates; cancer; cost

Mesh:

Year:  2013        PMID: 23419136      PMCID: PMC3661763          DOI: 10.1111/odi.12080

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  20 in total

Review 1.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.

Authors:  Cesar A Migliorati; Michael A Siegel; Linda S Elting
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

Review 2.  Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.

Authors:  Jose V Bagan; Yolanda Jimenez; Judith Murillo; Sergio Hernandez; Rafael Poveda; José M Sanchis; José M Diaz; Crispian Scully
Journal:  Oral Oncol       Date:  2005-11-04       Impact factor: 5.337

3.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

4.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

5.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Authors:  Aristotle Bamias; Efstathios Kastritis; Christina Bamia; Lia A Moulopoulos; Ioannis Melakopoulos; George Bozas; Vassiliki Koutsoukou; Dimitra Gika; Athanasios Anagnostopoulos; Christos Papadimitriou; Evagelos Terpos; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

6.  Surgical management of bisphosphonate induced osteonecrosis of the jaws.

Authors:  R A Williamson
Journal:  Int J Oral Maxillofac Surg       Date:  2009-12-16       Impact factor: 2.789

7.  Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

Authors:  Joan C Lo; Felice S O'Ryan; Nancy P Gordon; Jingrong Yang; Rita L Hui; Daniel Martin; Matthew Hutchinson; Phenius V Lathon; Gabriela Sanchez; Paula Silver; Malini Chandra; Carolyn A McCloskey; Judy A Staffa; Mary Willy; Joe V Selby; Alan S Go
Journal:  J Oral Maxillofac Surg       Date:  2009-09-24       Impact factor: 1.895

8.  Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs.

Authors:  Beatrice J Edwards; John W Hellstein; Peter L Jacobsen; Steven Kaltman; Angelo Mariotti; Cesar A Migliorati
Journal:  J Am Dent Assoc       Date:  2008-12       Impact factor: 3.634

9.  Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Authors:  Aliya A Khan; George K B Sándor; Edward Dore; Archibald D Morrison; Mazen Alsahli; Faizan Amin; Edmund Peters; David A Hanley; Sultan R Chaudry; David W Dempster; Francis H Glorieux; Alan J Neville; Reena M Talwar; Cameron M Clokie; Majd Al Mardini; Terri Paul; Sundeep Khosla; Robert G Josse; Susan Sutherland; David K Lam; Robert P Carmichael; Nick Blanas; David Kendler; Steven Petak; Louis Georges St-Marie; Jacques Brown; A Wayne Evans; Lorena Rios; Juliet E Compston
Journal:  J Rheumatol       Date:  2008-06-01       Impact factor: 4.666

Review 10.  A review of bisphosphonate-associated osteonecrosis of the jaws and its management.

Authors:  David K Lam; George K B Sándor; Howard I Holmes; A Wayne Evans; Cameron M L Clokie
Journal:  J Can Dent Assoc       Date:  2007-06       Impact factor: 1.316

View more
  3 in total

1.  The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.

Authors:  Daniel H Solomon; Amanda R Patrick; John Schousboe; Elena Losina
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

Review 2.  Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.

Authors:  Christian Thomas; Georg Bartsch; Christian Walter; Hendrik Borgmann; Maximilian Peter Brandt; Thomas Höfner; Axel Haferkamp; Igor Tsaur
Journal:  Dent J (Basel)       Date:  2016-08-19

3.  Up to 7% of referrals to oral and maxillofacial surgery are related to medication-related osteonecrosis of the jaws: how much is really out there?

Authors:  Ailish Clark; Iain Pretty
Journal:  BDJ Open       Date:  2022-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.